| 2023-10 |
Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs |
Annals of Oncology. 2023 Oct;34(Suppl. 2):S214. |
|
| 2020-08 |
BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification |
Cancer Research. 2020 Aug;80(16):1937. |
|
| 2019-10 |
Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer |
Annals of Oncology. 2019 Oct;30(Suppl. 5):789. |
 |
| 2019-07 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227. |
|
| 2019-07 |
An Aurora kinase inhibitor BPR6K471 inhibits tumor growth and reduces the cancer stem cell-like properties of small cell lung cancer |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 3851. |
|
| 2018-07 |
4-Bromophenylhydrazinyl benzenesulfonylphenylureas inhibit indoleamine 2,3-dioxygenase in vitro and in vivo |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 1664. |
|
| 2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer |
Cancer Science. 2018 Jan;109(Suppl. 1):739. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2016-12 |
Phenyl benzenesulfonylhydrazides: Selective indoleamine 2,3-dioxygenase inhibitors with potent in vivo pharmacodynamic activity and antitumor efficacy |
European Journal of Cancer. 2016 Dec;68(Suppl. 1):S83-S84. |
|
| 2016-12 |
Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P. |
|
| 2015-08 |
Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform |
Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
| 2013-04-13 |
Exploration of the role of tylophorine E ring in anti-Coronavirus activity-Tylophorine derived dibenzoquinolines impart multi-biological activities as orally active agents |
FASEB Journal. 2013 Apr 13;27:lb71. |
|
| 2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI. |
|
| 2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI. |
|
| 2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112 |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI. |
|
| 2012-11 |
BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia |
European Journal of Cancer. 2012 Nov;48(Suppl. 6):53-54. |
|
| 2011-03-27 |
Design and synthesis of potent Aurora kinase inhibitors |
Abstracts of Papers - American Chemical Society. 2011 Mar 27;241:258-MEDI. |
|
| 2011-03 |
Potent EGFR tyrosine kinase inhibitors as anticancer agents |
Abstracts of Papers - American Chemical Society. 2011 Mar;241:257-MEDI. |
|
| 2007-10 |
Differential effects of arsenic on cyp1 enzymes in vitro and in vivo |
Drug Metabolism Reviews. 2007 Oct;39(Suppl. 1):209. |
|
